drugset / Trial / NCT01195480
CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)
Phase 1/2
Terminated
29 enrolled
University College, London
Children with Leukaemia · collabDepartment of Health, United Kingdom · collabDeutsche Krebshilfe e.V., Bonn (Germany) · collabEuropean Union · collabJP Moulton Charitable Foundation · collabThe Leukemia and Lymphoma Society · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The aim of this clinical trial is to evaluate the feasibility, safety and biological effect of adoptive transfer of CD19ζ chimaeric receptor transduced donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTL) in patients with high-risk or relapsed B cell precursor ALL after allogeneic Haematopoietic Stem Cell Transplantation (HSCT).
Timeline
- Start
- 2012-05
- Primary completion
- 2015-11
- Completion
- 2015-11
Outcome
Outcome not reported
Stopped: “Due to lack of biological efficacy and CD19 CAR CTL persistence”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) | Cell therapy | 2e+08 unknown | — |
| Subject | donor-derived Lymphoblastoid Cell Line | Vaccine | 5e+06 cells | Subcutaneous |